Tipifarnib
As of the edition of 20 October 2026, Tipifarnib is a small molecule: stopped in 2023; acts on FNTA and FNTB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 89, 11 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Inherited and neonatal; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route A because of this drug.
Companies on route A for this drug
In the product1 company-target row is on route A because of Tipifarnib.
See the 1 company-target row on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 24 | 20 | 0 | 3 |
| Phase 2 | 60 | 47 | 3 | 8 |
| Phase 3 | 4 | 4 | 0 | 0 |
| All trials | 89 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Johnson & Johnson | Lead sponsor of trials | 1999 to now |
| Kura Oncology | Lead sponsor of trials | 2021 to now |